The aim of this technology assessment, which has been commissioned by NICE through the NIHR SR Programme as part of the NICE Single Technology Appraisal process, is to review the submission received from Novartis on the clinical and cost-effectiveness evidence of Secukinumab (Cosentyx®) for treating plaque psoriasis in children and young people. The primary source of clinical effectiveness evidence submitted by Novartis consists of a Phase III RCT (A2310) comparing secukinumab with placebo and etanercept in patients with severe disease. The Aberdeen HTA Group acts as the Evidence Review Group (ERG) for this technology appraisal and provides an independent critique of the clinical and cost-effectiveness evidence submitted by the company. Based on the findings of the submission received from Novartis and the ERG’s critique, NICE will release appropriate clinical guidance.
For more information see: https://www.nice.org.uk/guidance/indevelopment/gid-ta10554
- Miriam Brazzelli; firstname.lastname@example.org